In 2017, both GlaxoSmithKline (GSK) and Dynavax Technologies emerged as clear winners in the vaccines marketplace due to highly anticipated vaccine approvals in the US.

GSK’s Shingrix received the coveted ACIP recommendation in the US, positioning the firm as the dominant player in an anticipated multi-billion-dollar herpes zoster vaccine marketplace. Shingrix’s superior efficacy in adults ≥50 years of age led the ACIP to recommend it over Merck’s Zostavax.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Projected global market shares for herpes zoster (shingles) vaccines approved as of 2017

 

Source: GlobalData, Pharma Intelligence Center; figures ($M) represent projected 2017 and 2023 global sales

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In November 2017, Dynavax received long-awaited FDA approval for its hepatitis B vaccine, Heplisav-B. To assuage safety concerns surrounding its adjuvant, the vaccine was investigated in over 12,000 adults across five Phase III clinical trials.

Heplisav-B’s superior efficacy and dosing schedule compared with GSK’s Engerix-B should allow it to quickly garner market share in the US. Dynavax is opting to commercialise Heplisav-B alone, foregoing partnerships with more experienced vaccine distributors.

Projected global sales ($m) of Heplisav-B, 2017–2023

Source: GlobalData, Pharma Intelligence Center; figures ($M) represent projected global sales